Trevena Appoints Francois Nader, MD, to its Board of Directors

Jan 08, 2014 7:00am EST

First Clinical Experience of Trevena's lead CNS Biased Ligand, TRV130, Published in Journal of Clinical Pharmacology

Oct 15, 2013 8:00am EDT

Trevena Files Registration Statement for Proposed Initial Public Offering

Oct 10, 2013 7:00am EDT

Trevena Appoints Roberto Cuca as Senior Vice President & Chief Financial Officer

Sep 17, 2013 1:18pm EDT

Mechanism for Cardiac Effects of Trevena Angiotensin Receptor Biased Ligands Examined in Published Study

Jul 30, 2013 7:00am EDT

Trevena Granted Key Composition of Matter Patent for TRV027 in U.S.

Jul 17, 2013 7:00am EDT

Journal of Clinical Pharmacology Publishes First Clinical Experience with Trevena's Heart Failure Biased Ligand TRV027

Jul 08, 2013 7:00am EDT

Trevena, Inc. and Forest Laboratories Announce a Collaborative Agreement For Development of TRV027 for the Treatment of Acute Heart Failure

May 09, 2013 6:00am EDT

Trevena, Inc. to Present at the 12th Annual Needham Healthcare Conference

Apr 22, 2013 9:00am EDT

Trevena to Present First-in-Man Study Results for Mu-Opioid Biased Ligand TRV130

Mar 18, 2013 9:00am EDT